Skip to main
XFOR
XFOR logo

XFOR Stock Forecast & Price Target

XFOR Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

X4 Pharmaceuticals Inc has demonstrated a proactive approach in its clinical development strategy by increasing the enrollment target for the pivotal 4WARD study to 176 participants, ensuring a comprehensive data package for regulatory review. The anticipated label expansion of mavorixafor into additional primary immunodeficiency disorders, coupled with robust biological validation for CXCR4 inhibition, positions the company for potentially significant market opportunities. Furthermore, a successful financing round has bolstered the company's cash position, projecting approximately $130 million by the end of the third quarter of 2025, which enhances its financial flexibility to support ongoing and future development initiatives.

Bears say

The analysis indicates several fundamental concerns regarding X4 Pharmaceuticals's financial outlook. Key issues include a significant decrease in the projected target price from $30 to $9, driven largely by delayed patient enrollment timelines for the 4WARD trial and reduced sales estimates for its WHIM syndrome treatment, leading to expectations of peak sales dropping from approximately $140 million to $75-80 million. Additionally, the company faces a challenging balance sheet situation exacerbated by anticipated dilution from PIPE and ATM financing, leading to further uncertainty regarding future funding requirements amid ongoing operational and strategic reviews by new management.

XFOR has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of X4 Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About X4 Pharmaceuticals Inc (XFOR) Forecast

Analysts have given XFOR a Strong Buy based on their latest research and market trends.

According to 3 analysts, XFOR has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

X4 Pharmaceuticals Inc (XFOR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.